Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 13.

Riedel, T; Ghasparian, A; Moehle, K; Rusert, P; Trkola, A; Robinson, J A (2011). Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design. ChemBioChem, 12(18):2829-2836.

Rusert, P; Krarup, A; Magnus, C; Brandenberg, O F; Weber, J; Ehlert, A K; Regoes, R R; Günthard, H F; Trkola, A (2011). Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. Journal of Experimental Medicine, 208(7):1419-1433.

Ruprecht, C R; Krarup, A; Reynell, L; Mann, A M; Brandenberg, O F; Berlinger, L; Abela, I A; Regoes, R R; Günthard, H F; Rusert, P; Trkola, A (2011). MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. Journal of Experimental Medicine, 208(3):439-454.

Haas, A; Zimmermann, K; Graw, F; Slack, E; Rusert, P; Ledergerber, B; Bossart, W; Weber, R; Thurnheer, M C; Battegay, M; Hirschel, B; Vernazza, P; Patuto, N; Macpherson, A J; Günthard, H F; Oxenius, A (2011). Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut, 60(11):1506-1519.

Joos, B; Rieder, P; Fischer, M; Kuster, H; Rusert, P; Trkola, A; Pillai, S K; Wong, J K; Weber, R; Günthard, H F (2010). Association between specific HIV-1 Env traits and virologic control in vivo. Infection, Genetics and Evolution, 10(3):365-372.

Haas, A; Rehr, M; Graw, F; Rusert, P; Bossart, W; Kuster, H; Trkola, A; Günthard, H F; Oxenius, A (2010). HIV-1 replication activates CD4+ T cells with specificities for persistent herpes viruses. EMBO Molecular Medicine, 2(6):231-244.

Seitz, M; Rusert, P; Moehle, K; Trkola, A; Robinson, J A (2010). Peptidomimetic inhibitors targeting the CCR5-binding site on the human immunodeficiency virus Type-1 gp120 glycoprotein complexed to CD4. Chemical Communications, 46(41):7754-7756.

Magnus, C; Rusert, P; Bonhoeffer, S; Trkola, A; Regoes, R R (2009). Estimating the stoichiometry of HIV entry. Journal of Virology, 83(3):1523-1531.

Rusert, P; Mann, A; Huber, M; von Wyl, V; Gunthard, H F; Trkola, A (2009). Divergent effects of cell environment on HIV entry inhibitor activity. AIDS, 23(11):1319-1327.

Mann, A M; Rusert, P; Berlinger, L; Kuster, H; Günthard, H F; Trkola, A (2009). HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS, 23(13):1659-1667.

Trkola, A; Kuster, H; Rusert, P; von Wyl, V; Leemann, C; Weber, R; Stiegler, G; Katinger, H; Joos, B; Günthard, H F (2008). In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. Journal of Virology, 82(3):1591-1599.

Schweizer, A; Rusert, P; Berlinger, L; Ruprecht, C R; Mannhart, A; Corthésy, S; Turville, S G; Aravantinou, M; Fischer, M; Robbiani, M; Amstutz, P; Trkola, A (2008). CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS Pathogens, 4(7):e1000109.

Joos, B; Trkola, A; Fischer, M; Kuster, H; Rusert, P; Leemann, C; Böni, J; Oxenius, A; Price, D A; Phillips, R E; Wong, J K; Hirschel, B; Weber, R; Günthard, H F (2005). Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. Journal of Virology, 79(14):9026-9037.

This list was generated on Fri Sep 20 17:00:45 2019 CEST.